Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, placebo-controlled, adaptive design, multi-center
study of the long-term cardiovascular and breast safety of LibiGel in the treatment of HSDD
in postmenopausal women with at least two points of cardiovascular risk and clinical
diagnosis of Hypoactive Sexual Desire Disorder (HSDD).